AT9283

Known as: AT 9283, AT-9283 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2017
02420092017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
PURPOSE A phase I trial of AT9283 (a multitargeted inhibitor of Aurora kinases A and B) was conducted in children and adolescents… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2012
2012
Aurora kinases are oncogenic serine/threonine kinases that play key roles in regulating the mitotic phase of the eukaryotic cell… (More)
Is this relevant?
2012
2012
BACKGROUND AT9283 is an inhibitor of aurora kinases A and B with antitumor activity in preclinical models. This a First in Human… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2011
2011
PURPOSE Aurora kinases, whose expression is linked to genetic instability and cellular proliferation, are being investigated as… (More)
Is this relevant?
2011
2011
Non-invasive assessment of biomarker modulation is important for evaluating targeted therapeutics, particularly in pediatrics… (More)
Is this relevant?
2010
2010
Constitutive activation of Janus kinase (Jak) 2 is the most prevalent pathogenic event observed in the myeloproliferative… (More)
Is this relevant?
2010
2010
Despite promising clinical results from imatinib mesylate and second-generation ABL tyrosine kinase inhibitors (TKIs) for most… (More)
  • table 2
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Here, we describe the identification of a clinical candidate via structure-based optimization of a ligand efficient pyrazole… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • table 2
Is this relevant?
2009
2009
2566 Background: AT9283, a multitargeted kinase inhibitor, inhibits several closely related tyrosine and serine/threonine kinases… (More)
Is this relevant?
2009
2009
Aurora kinases play a key role in regulating mitotic division and are attractive oncology targets. AT9283, a multi-targeted… (More)
Is this relevant?